Definiens and Clarient sign agreement over image analysis software

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

DEFINIENS and Clarient Diagnostic Services Inc. signed an agreement to extend the use of Definiens’ automated image analysis software and solutions in Clarient’s validated clinical applications for immunohistochemistry testing in breast cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

The landscape of cancer care in America faces critical challenges: geographic disparities in access, socioeconomic barriers to advanced treatments and the increasing complexity of precision medicine that outpaces individual providers’ ability to stay current. At City of Hope, we are addressing these systemic issues through a bold expansion that brings world-class cancer care and research closer to where patients live.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login